Table 1.
Glycemic efficacy of dapagliflozin when used as monotherapy in patients with type 2 diabetes mellitus
| Study | Intervention | Mean change from baseline HbA1c, % |
|---|---|---|
| List et al. [45] | Placebo (n = 54) | −0.18 |
| Dapagliflozin 2.5 mg (n = 59) | −0.71** | |
| Dapagliflozin 5 mg (n = 58) | −0.72** | |
| Dapagliflozin 10 mg (n = 47) | −0.85** | |
| Dapagliflozin 20 mg (n = 59) | −0.55* | |
| Dapagliflozin 50 mg (n = 56) | −0.90** | |
| Metformin XR 750/1500 mg (n = 56) | −0.73 | |
| Ferrannini et al. [43] | Placebo (n = 75) | −0.23 |
| Dapagliflozin 2.5 mg a.m. (n = 65) | −0.58 | |
| Dapagliflozin 5 mg a.m. (n = 64) | −0.77** | |
| Dapagliflozin 10 mg a.m. (n = 70) | −0.89† | |
| Dapagliflozin 2.5 mg evening (n = 67) | −0.83 | |
| Dapagliflozin 5 mg evening (n = 68) | −0.79 | |
| Dapagliflozin 10 mg evening (n = 76) | −0.79 | |
| Bailey et al. [42] | Placebo (n = 68) | 0.02 |
| Dapagliflozin 1 mg (n = 72) | −0.68† | |
| Dapagliflozin 2.5 mg (n = 74) | −0.72† | |
| Dapagliflozin 5 mg (n = 68) | −0.82† | |
| Henry et al. [47] | Dapagliflozin 5 mg (n = 203) | −1.19 |
| Metformin XR 2000 mg (n = 201) (study 1) | −1.35 | |
| Dapagliflozin 10 mg (n = 219) | −1.45 | |
| Metformin XR 2000 mg (n = 208) (study 2) | −1.44 | |
| Kaku et al. [46] | Placebo (n = 54) | 0.37 |
| Dapagliflozin 1 mg (n = 59) | −0.12** | |
| Dapagliflozin 2.5 mg (n = 56) | −0.11** | |
| Dapagliflozin 5 mg (n = 58) | −0.37** | |
| Dapagliflozin 10 mg (n = 52) | −0.44** | |
| Ji et al. [44] | Placebo (n = 132) | −0.29 |
| Dapagliflozin 5 mg (n = 128) | −1.04 | |
| Dapagliflozin 10 mg (n = 133) | −1.11 | |
| Kaku et al. [25] | Placebo (n = 87) | −0.06 |
| Dapagliflozin 5 mg (n = 86) | −0.41† | |
| Dapagliflozin 10 mg (n = 88) | −0.45† |
a.m. morning, HbA 1c, glycosylated hemoglobin
* P < 0.01 vs. placebo, ** P < 0.001 vs. placebo, † P < 0.0001 vs. placebo